PCDH17, protocadherin 17, 27253

N. diseases: 51; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280324
Disease: Laryngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma 		0.030 AlteredExpression disease BEFREE And low expression of miR-196b and high expression of PCDH-17 contributed to an increase in the 5-year-survival rate of LSCC patients. 30454973 2019
CUI: C0280324
Disease: Laryngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma 		0.030 Biomarker disease BEFREE High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. 21213369 2011
CUI: C0280324
Disease: Laryngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma 		0.030 PosttranslationalModification disease BEFREE In conclusion, we provide a mechanistic explanation of recurrently observed PCDH17 silencing in LSCC by demonstrating the role of promoter methylation in this process. 29566279 2018
CUI: C0279702
Disease: Conventional (Clear Cell) Renal Cell Carcinoma
Conventional (Clear Cell) Renal Cell Carcinoma 		0.020 PosttranslationalModification disease BEFREE PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. 26404644 2015
CUI: C0279702
Disease: Conventional (Clear Cell) Renal Cell Carcinoma
Conventional (Clear Cell) Renal Cell Carcinoma 		0.020 Biomarker disease BEFREE Moreover, PCDH17 methylation in serum is a potential prognostic biomarker for patients with RCC after surgery. 28688232 2017
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder 		0.010 AlteredExpression disease BEFREE The risk allele predicted higher transcriptional levels of PCDH17 mRNA in postmortem brain samples, which is consistent with increased gene expression in patients with bipolar disorder compared with healthy subjects. 28070120 2018
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 AlteredExpression disease BEFREE Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter. 27351130 2016
CUI: C0007134
Disease: Renal Cell Carcinoma
Renal Cell Carcinoma 		0.010 Biomarker disease BEFREE Moreover, PCDH17 methylation in serum is a potential prognostic biomarker for patients with RCC after surgery. 28688232 2017
CUI: C0017154
Disease: Gastritis, Atrophic
Gastritis, Atrophic 		0.010 AlteredExpression disease BEFREE In the protein expression analysis, PCDH17 expression was inversely associated with gastric lesions; the OR [95% confidence interval (CI)] was 0.49 (0.26-0.95) for chronic atrophic gastritis (CAG), 0.31 (0.15-0.63) for intestinal metaplasia, and 0.38 (0.19-0.75) for indefinite dysplasia and dysplasia, compared with superficial gastritis. 30213786 2018
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.010 Biomarker disease BEFREE PCDH17 methylation at diagnosis was closely related to poor prognosis and thus could be used as a new biomarker to predict relapse in patients with BCP ALL. 27643535 2017
CUI: C0023452
Disease: Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia 		0.010 Biomarker disease BEFREE PCDH17 methylation at diagnosis was closely related to poor prognosis and thus could be used as a new biomarker to predict relapse in patients with BCP ALL. 27643535 2017
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.010 AlteredExpression disease BEFREE Moreover, low PCDH17 expression predicted worse overall survival (OS) in four independent cohorts as well as in the molecularly defined subgroups of AML patients. 30922328 2019
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach 		0.010 AlteredExpression disease BEFREE PCDH17 mRNA expression in pairs of gastric cancer and normal tissue samples and cell lines were determined by quantitative real-time polymerase chain reaction. 22207556 2012
CUI: C0029925
Disease: Ovarian Carcinoma
Ovarian Carcinoma 		0.010 PosttranslationalModification disease BEFREE PCDH17 methylation was detected in almost 70% of HGSOC patients without any methylation in the group of control samples and was found both in the late stage tumors as well as in the early stage ones. 29991130 2018
CUI: C0039144
Disease: Syringomyelia
Syringomyelia 		0.010 GeneticVariation disease BEFREE We identified 2 loci on CFA22 and CFA26 that contained only 2 genes, PCDH17 and ZWINT, significantly associated to two traits associated with syrinx transverse diameter. 29566674 2018
CUI: C0039147
Disease: Syrinx formation
Syrinx formation 		0.010 GeneticVariation disease BEFREE We identified 2 loci on CFA22 and CFA26 that contained only 2 genes, PCDH17 and ZWINT, significantly associated to two traits associated with syrinx transverse diameter. 29566674 2018
CUI: C0153392
Disease: Malignant neoplasm of nasopharynx
Malignant neoplasm of nasopharynx 		0.010 PosttranslationalModification disease BEFREE Aberrant promoter methylation reduced the expression of protocadherin 17 in nasopharyngeal cancer. 30165032 2019
CUI: C0238301
Disease: Cancer of Nasopharynx
Cancer of Nasopharynx 		0.010 PosttranslationalModification disease BEFREE Aberrant promoter methylation reduced the expression of protocadherin 17 in nasopharyngeal cancer. 30165032 2019
CUI: C0267159
Disease: Superficial gastritis
Superficial gastritis 		0.010 AlteredExpression disease BEFREE In the protein expression analysis, PCDH17 expression was inversely associated with gastric lesions; the OR [95% confidence interval (CI)] was 0.49 (0.26-0.95) for chronic atrophic gastritis (CAG), 0.31 (0.15-0.63) for intestinal metaplasia, and 0.38 (0.19-0.75) for indefinite dysplasia and dysplasia, compared with superficial gastritis. 30213786 2018
CUI: C0279626
Disease: Squamous cell carcinoma of esophagus
Squamous cell carcinoma of esophagus 		0.010 PosttranslationalModification disease BEFREE These results suggest that silencing of PCDH17 expression through hypermethylation of the promoter or other mechanisms leads to loss of its tumour-suppressive activity, which may be a factor in the carcinogenesis of a subgroup of ESCCs. 20200074 2010
CUI: C0279680
Disease: Transitional cell carcinoma of bladder
Transitional cell carcinoma of bladder 		0.010 PosttranslationalModification disease BEFREE Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. 24567353 2014
CUI: C0280141
Disease: Acute Undifferentiated Leukemia
Acute Undifferentiated Leukemia 		0.010 AlteredExpression disease BEFREE We identified protocadherin17 (PCDH17) and demonstrated that it was significantly down-regulated and hypermethylated in LSCs compared with HSCs. 30922328 2019
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.010 PosttranslationalModification disease BEFREE In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer. 25091018 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.010 PosttranslationalModification disease BEFREE In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer. 25091018 2014
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 AlteredExpression disease BEFREE Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter. 27351130 2016